Unpacking the Complexity of the Most Favored Nation Mandate

Drug prices, patient access, and pharmaceutical innovation drove the first part of a 3-part webinar series that will examine the impact of President Donald J. Trump’s May 12 Most Favored Nation (MFN) executive order.¹ On September 10, Ned Milenkovich, PharmD, JD, chair of the health care practice at Much Shelist PC, moderated the in-depth discussion, “The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients,” and he was joined by thought leaders representing experiences from life sciences commercial and market access strategy, health economics, health care investment banking, and strategic planning: